Security key
03836J201
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE)
CUSIP: 03836J201
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common stock, par value $0.001 per share
- Shares outstanding
- 9,144,889
- Total 13F shares
- 1,695,512
- Share change
- +66,461
- Total reported value
- $1,446,275
- Price per share
- $0.85
- Number of holders
- 22
- Value change
- -$113,007
- Number of buys
- 9
- Number of sells
- 12
Report period
Q4 2025
Institutions
22
Top holders
10
APRE full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Aprea Therapeutics, Inc. SEC filings
Aprea Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 03836J201
Recent filing periods:
Top shareholders of APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Christian S. Schade |
3/4/5
|
Director |
—
mixed-class rows
|
312,846
mixed-class rows
|
$976,345 | — | 28 Jul 2022 | |
| Laurence W. Lytton |
13D/G
|
LYTTON LAURENCE W |
9.9%
|
681,837
|
$913,662 | $0 | 13 Nov 2025 | |
| AIGH Capital Management LLC |
13F
|
Company |
5.9%
|
539,300
|
$795,467 | — | 30 Sep 2025 | |
| Scott M. Coiante |
3/4/5
|
SVP, Chief Financial Officer |
—
mixed-class rows
|
234,265
mixed-class rows
|
$533,970 | — | 28 Jul 2022 | |
| Stonepine Capital Management, LLC |
13D/G
|
— |
4.3%
|
239,416
|
$418,978 | -$82,213 | 31 Mar 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
3%
|
270,000
|
$398,250 | — | 30 Sep 2025 | |
| Nantahala Capital Management, LLC |
13D/G
13F
|
Company |
4.5%
|
411,520
|
$386,829 | $0 | 31 Dec 2025 | |
| Marc Duey |
3/4/5
|
Director |
—
mixed-class rows
|
282,401
mixed-class rows
|
$299,226 | +$25,000 | 10 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.7%
|
158,238
|
$233,401 | — | 30 Sep 2025 | |
| Eyal C. Attar |
3/4/5
|
SVP, Chief Medical Officer, Director |
—
class O/S missing
|
57,392
|
$211,254 | — | 03 Jun 2022 | |
| DAFNA Capital Management LLC |
13F
|
Company |
1.5%
|
137,174
|
$202,332 | — | 30 Sep 2025 | |
| Gregory Alan Korbel |
3/4/5
|
SVP, Chief Operating Officer |
—
mixed-class rows
|
81,462
mixed-class rows
|
$168,445 | — | 28 Jul 2022 | |
| Sio Capital Management, LLC |
13F
13D/G
|
Company |
1.9%
from 13D/G
|
112,223
|
$165,529 | — | 30 Sep 2025 | |
| Lars B. Abrahmsen |
3/4/5
|
SVP, Chief Scientific Officer |
—
mixed-class rows
|
143,700
mixed-class rows
|
$160,855 | — | 10 Mar 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.72%
|
65,808
|
$97,067 | — | 30 Sep 2025 | |
| Bernd R. Seizinger |
3/4/5
|
Director |
—
mixed-class rows
|
54,145
mixed-class rows
|
$74,155 | — | 05 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.49%
|
44,616
|
$65,818 | — | 30 Sep 2025 | |
| Nadeem Q. Mirza |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
33,650
mixed-class rows
|
$49,062 | — | 01 May 2024 | |
| Rifat Pamukcu |
3/4/5
|
Director |
—
mixed-class rows
|
27,924
mixed-class rows
|
$31,676 | — | 05 Jun 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.19%
|
17,132
|
$25,270 | — | 30 Sep 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.18%
|
16,052
|
$23,677 | — | 30 Sep 2025 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.15%
|
13,864
|
$20,449 | — | 30 Sep 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.13%
|
12,264
|
$18,000 | — | 30 Sep 2025 | |
| Fouad Namouni |
3/4/5
|
Director |
—
mixed-class rows
|
27,360
mixed-class rows
|
$16,969 | — | 30 Jun 2021 | |
| Michael Aaron Kelly |
3/4/5
|
Director |
—
mixed-class rows
|
27,360
mixed-class rows
|
$16,969 | — | 30 Jun 2021 | |
| John B. Henneman III |
3/4/5
|
Director |
—
mixed-class rows
|
18,599
mixed-class rows
|
$16,570 | — | 05 Jun 2025 | |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
0.11%
|
10,496
|
$15,481 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.09%
|
8,504
|
$12,543 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.05%
|
4,861
|
$7,170 | — | 30 Sep 2025 | |
| Michael Grissinger |
3/4/5
|
Director |
—
mixed-class rows
|
11,259
mixed-class rows
|
$4,680 | — | 05 Jun 2025 | |
| Gabriela Gruia |
3/4/5
|
Director |
—
mixed-class rows
|
5,230
mixed-class rows
|
$1,692 | — | 05 Jun 2025 | |
| Jean-Pierre Bizzari |
3/4/5
|
Director |
—
mixed-class rows
|
5,230
mixed-class rows
|
$1,692 | — | 05 Jun 2025 | |
| MB, LEVIS & ASSOCIATES, LLC |
13F
|
Company |
0.01%
|
806
|
$1,189 | — | 30 Sep 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.01%
|
577
|
$851 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
568
|
$838 | — | 30 Sep 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
400
|
$609 | — | 30 Sep 2025 | |
| WealthCollab, LLC |
13F
|
Company |
0%
|
158
|
$234 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
42
|
$62 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
5
|
$7 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
3
|
$4 | — | 30 Sep 2025 |
Institutional Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q4 2025
As of 31 Dec 2025,
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) was held by
22 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,695,512 shares.
The largest 10 holders included
AIGH Capital Management LLC, Murchinson Ltd., SPHERA FUNDS MANAGEMENT LTD., Nantahala Capital Management, LLC, DRW Securities, LLC, MORGAN STANLEY, VANGUARD GROUP INC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
22
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
23
Q4 2025 holders
22
Holder diff
-1
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.